Follow
the Money with Dr. Fauci and Covid-19 by J. Parnell McCarter
This is the second
article in a series exploring the questionable conduct of Dr. Fauci related to Covid-19. Others are http://www.puritans.net/articles/fauci.htm
and http://www.puritans.net/articles/fauci3.htm.
There are many angles to
explore if Covid-19 is human-engineered and Dr. Fauci
is connected with the impropriety, but surely one angle should be the money
angle: which parties would stand to profit from Covid-19 financially without
dissipating the likely other objectives to be achieved (see http://www.puritans.net/articles/fauci.htm
), and how is Dr. Fauci connected to them? In other words, “follow the money”, for those
like Judas Iscariot generally arrange financial gain as part of their scheme.
So far Gilead Sciences' remdesivir fits
the bill of a drug making lots of money for some well-connected parties but
doing very little to solve the Covid-19 pandemic, but rather to take it down a
rabbit trail while more die. Oh, and there is a Jesuit-linked partnership at
work in this impropriety: Dr. Anthony Fauci (head of
NIAID) and Daniel O’Day (head of Gilead Sciences).
Follow the logic of this series of quotes from
publicly verifiable sources:
https://www.biospace.com/article/fda-grants-eau-to-gilead-sciences-remdesivir/
-
“The U.S. Food and Drug Administration (FDA)
approved Gilead's remdesivir
under Emergency Use Authorization as a treatment for COVID-19 following reports
the drug met its primary endpoint in a U.S. National Institute of Allergy and
Infectious Diseases (NIAID) clinical trial. The EAU came barely 48 hours after
results from the NIAID trial that showed COVID-19 patients receiving remdesivir had a 31% faster time to recovery than the
placebo group. As BioSpace reported this week,
patients who received remdesivir recovered about four
days faster than those on placebo, a median of 11 days versus 15 days, respectively. Survival
benefit was not statistically significant, according to the results, about 8%
compared to 11.6% for the placebo group. But, the
results do suggest a survival benefit. In its announcement this afternoon, the
FDA noted that until this EAU, there had been no medicines approved by the FDA
that have been considered safe and effective to treat people in the hospital
who have COVID-19. Under the dosing provisions of the EAU, remdesivir
is delivered intravenously one time per day for up to 10 days.”
So per the article above, the only FDA-approved
drug for Covid-19 is remdesivir, and it had to be so
approved by Emergency Use Authorization because it has not been proven to work. It received this special treatment despite the
fact that it must be delivered intraveneously, which
means patients must be hospitalized to receive it. This is significant not only
from a cost standpoint, but because many hospitals have become death traps (see,
for example, https://www.businessinsider.com/healthcare-workers-who-died-with-the-coronavirus-2020-4#larrice-anderson-46-died-of-the-coronavirus-disease-on-march-31-she-worked-as-a-nurse-for-12-years-in-new-orleans-louisiana-12
). In addition, remdesivir is newer and has less
history, as well as being under patent, unlike a number of other promising
treatments in which there is far more evidence of effectivity, like
hydroxychloroquine (see https://eyewire.news/articles/aaps-hydroxychloroquine-has-about-90-percent-chance-of-helping-covid-19-patients/
). (Note: The study done by the
University of Minnesota was highly problematic, because those receiving hydroxychloroquine
were sicker that the control group, by the test authors own admission per https://www.cidrap.umn.edu/news-perspective/2020/05/study-finds-no-hydroxychloroquine-effect-death-severe-covid-19
.)
https://en.wikipedia.org/wiki/Remdesivir
-
“…Remdesivir was
rapidly pushed through clinical trials due to the West African Ebola virus epidemic of 2013–2016, eventually being used in
people with the disease. Preliminary results were promising; it was used in the
emergency setting during the Kivu Ebola epidemic that started in 2018, along with further clinical trials,
until August 2019, when Congolese health officials announced that it was
significantly less effective than monoclonal antibody treatments such as mAb114 and REGN-EB3…
As of April 2020, remdesivir
was viewed as the most promising treatment for COVID-19,[23] and was included among four
treatments under evaluation in the international Solidarity trial[24][25][26] and European Discovery trial.[27] The FDA stated on 1 May 2020, that
it is "reasonable to believe" that known and potential benefits of remdesivir outweigh its known and potential risks, in some
specific populations hospitalized with severe COVID‑19.[2]
On 29 April 2020, the National Institute of Allergy and Infectious Diseases
(NIAID) announced that remdesivir was better than a placebo in reducing time to recovery for
people hospitalized with advanced COVID‑19 and lung involvement.[6] Previously data from one randomized
controlled trial was released early in error and before peer review; it did not show improvement.
Gilead Sciences stated that due to low enrollment the study was halted while a
non-associated researcher stated it does mean if there is any benefit, then
that benefit will be small…
In a trial in China over
February-March 2020, remdesivir was not effective in
reducing the time for improvement from COVID‑19 or deaths, and caused
various adverse effects, requiring the investigators to terminate the trial…
On 1 May 2020, the U.S. Food and Drug Administration granted Gilead Emergency Use
Authorization of remdesivir to be
distributed and used by licensed health care providers to treat adults and
children hospitalized with severe COVID‐19.[3][11] Severe COVID‐19 is defined as
patients with an oxygen saturation (SpO2) ≤ 94% on room air or requiring
supplemental oxygen or requiring mechanical ventilation or requiring
extracorporeal membrane oxygenation (ECMO), a heart‐lung bypass machine.[52][11][53][54] Distribution of remdesivir
under the EUA will be controlled by the U.S. government for use consistent with
the terms and conditions of the EUA.[11] Gilead will supply remdesivir to authorized distributors, or directly to a
U.S. government agency, who will distribute to hospitals and other healthcare
facilities as directed by the U.S. Government, in collaboration with state and
local government authorities, as needed.[11]
On 7 May 2020, Japan's
Ministry of Health, Labour and Welfare
approved the drug for use in Japan, in a fast-tracked process based on the U.S.
emergency authorization.[4]
Gilead stated they were
donating 1.5 million vials for emergency use[53] and estimated, as of April 2020,
they had enough drug for 140,000 treatment courses and expect to have 500,000
courses by October 2020, and one million courses by the end of 2020…”
“The antiviral medicine remdesivir
from Gilead Sciences failed to speed the improvement of patients with Covid-19
or prevent them from dying, according to results from a long-awaited clinical
trial conducted in China. Gilead, however, said the data suggest a “potential
benefit.” A summary of the study results was inadvertently posted to the
website of the World Health Organization and seen by STAT on Thursday, but then
removed.”
“When the first data emerged Wednesday from a
placebo-controlled study of Gilead Sciences' remdesivir,
analysts agreed that it “appears to help,” but it was no “silver bullet.” But
it doesn’t need to be, said Anthony Fauci, M.D.,
director of the National Institutes of Health body that sponsored the study.
Instead, he sees the drug as a steppingstone to better treatments that could
even be combined for a greater effect—an idea also held by Gilead CEO Daniel O’Day.”
“Gilead
CEO says coronavirus drug remdesivir could reach
patients within days…We are now firmly focused on getting this
medicine to the most urgent patients around the country here in the United
States," Daniel O'Day, CEO of Gilead, said on
"Face the Nation." "We intend to get that to patients in the
early part of this next week, beginning to work with the government, which will
determine which cities are most vulnerable and where the patients are that need
this medicine."…
Food and Drug Administration Commissioner Stephen
Hahn announced Friday that remdesivir, produced by Gilead, received an emergency use
authorization for the treatment of patients in the hospital with COVID-19. A
recently completed study led by the
National Institutes of Health found that remdesivir
shortened the recovery time for some coronavirus patients by four days. The
drug is administered by IV through either a five-day treatment course or 10-day
treatment course depending on the patient.”
https://www.gilead.com/about/leadership/senior-management/daniel-oday
-
“Daniel O'Day holds a bachelor's degree in biology from Georgetown University and an MBA from Columbia University in New York. He currently serves on the board of directors for the Pharmaceutical Research and Manufacturers of America organization and Galapagos NV.”
https://brooksysociety.com/2020/04/24/gilead-sciences-ceo-daniel-oday-biography/
-
“Daniel describes his father as being very “literal.” He points to the man’s initial interview with IBM, explaining how the recruiters, maybe half-jokingly, told him they only hire people with master’s degrees. Having already completed his undergraduate at Gonzaga (being the first of his family to earn a college degree), he walked out and got a master’s in mathematics from Washington University…O’Day went on to do his undergraduate in biology at Georgetown University. When graduation came around, he pondered going to medical school but ultimately decided to join the business side of the healthcare industry.”
So O’Day’s father
went to Jesuit college Gonzaga, and O’Day did his
undergraduate at Jesuit Georgetown University. Dr. Fauci
too has Jesuit connections, as indicated at http://www.puritans.net/articles/fauci.htm .
Dr. Fauci
says his motto comes from “The Godfather”: ‘It’s nothing
personal, it’s strictly business.’” - https://www.newyorker.com/magazine/2020/04/20/how-anthony-fauci-became-americas-doctor
Dr. Fauci is certainly showing how “business” can pay.